Castle Biosciences Inc. (CSTL)
19.77
0.07 (0.36%)
At close: Apr 14, 2025, 1:15 PM
0.36% (1D)
| Bid | 19.67 |
| Market Cap | 570.12M |
| Revenue (ttm) | 332.07M |
| Net Income (ttm) | 18.25M |
| EPS (ttm) | 0.62 |
| PE Ratio (ttm) | 31.88 |
| Forward PE | -16.79 |
| Analyst | Strong Buy |
| Ask | 19.73 |
| Volume | 60,104 |
| Avg. Volume (20D) | 410,103 |
| Open | 20.02 |
| Previous Close | 19.70 |
| Day's Range | 19.52 - 20.09 |
| 52-Week Range | 16.96 - 35.84 |
| Beta | 1.11 |
About CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients w...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jul 25, 2019
Employees 761
Stock Exchange NASDAQ
Ticker Symbol CSTL
Website https://castlebiosciences.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $40, which is an increase of 102.38% from the latest price.
Stock ForecastsNext Earnings Release
Castle Biosciences Inc. is scheduled to release its earnings on May 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-14.24%
Castle Biosciences shares are trading lower. The c...
Unlock content with
Pro Subscription
3 months ago
-13.55%
Castle Biosciences shares are trading lower after the company reported preliminary FY24 financial results.
